Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Cutia Therapeutics

2487:HKG.HZ

Cutia Therapeutics

Actions
  • Price (HKD)12.00
  • Today's Change-0.94 / -7.26%
  • Shares traded209.60k
  • 1 Year change-40.59%
  • Beta--
Data delayed at least 15 minutes, as of Oct 15 2024 09:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)217.21m
  • Net income in HKD-572.76m
  • Incorporated2019
  • Employees360.00
  • Location
    Cutia Therapeutics436 Heng Feng RoadJingan District, 20/F, Huanzhi BuildingSHANGHAI ChinaCHN
  • Websitehttps://www.cutiatx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.